Alnylam Pharmaceuticals Inc

NASDAQ:ALNY  
177.00
+4.75 (+2.76%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)21.37B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$193.44 Million
Adjusted EPS-$1.61
See more estimates
10-Day MA$164.50
50-Day MA$142.96
200-Day MA$141.04
See more pivots

Alnylam Pharmaceuticals Inc Stock, NASDAQ:ALNY

675 West Kendall Street, Henri A. Termeer Square, Cambridge, Massachusetts 02142
Phone: +1.617.551.8200
Number of Employees: 1453

Description

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.